Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan

被引：3
|
作者：
Yun, Karen M. [1 ]
Bazhenova, Lyudmila [1 ]
机构：
[1] UC San Diego Hlth, Div Hematol Oncol, Moores Canc Ctr, La Jolla, CA 92122 USA
来源：
BMJ CASE REPORTS | 2023年 / 16卷 / 05期
关键词：
Lung cancer (oncology); Therapeutic indications; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2; GENE; IMMUNOHISTOCHEMISTRY; EXPRESSION; HER-2/NEU; SURVIVAL; MUTATION;
D O I：
10.1136/bcr-2022-253260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan
    Yun, K.
    Bazhenova, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E38 - E38
  • [2] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Li, Bob T.
    Smit, Egbert F.
    Goto, Yasushi
    Nakagawa, Kazuhiko
    Udagawa, Hibiki
    Mazieres, Julien
    Nagasaka, Misako
    Bazhenova, Lyudmila
    Saltos, Andreas N.
    Felip, Enriqueta
    Pacheco, Jose M.
    Perol, Maurice
    Paz-Ares, Luis
    Saxena, Kapil
    Shiga, Ryota
    Cheng, Yingkai
    Acharyya, Suddhasatta
    Vitazka, Patrik
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03): : 241 - 251
  • [3] Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer
    Tjong, Michael C.
    Mak, Raymond H.
    Louie, Alexander V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18): : 1770 - 1770
  • [4] CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
    Lazaratos, Anna-Maria
    Petrecca, Kevin
    Guiot, Marie-Christine
    Dankner, Matthew
    Jerzak, Katarzyna J.
    LANCET ONCOLOGY, 2024, 25 (07): : e282 - e282
  • [5] DESTINY-Lung01 Trial Investigators Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Sharayah, Ahmad
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (06) : 749 - 750
  • [6] Trastuzumab Emtansine in HER2+Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol
    Ohashi, Kadoaki
    Hotta, Katsuyuki
    Hirata, Taizo
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Ninomiya, Kiichiro
    Kayatani, Hiroe
    Yanai, Hiroyuki
    Toyooka, Shinichi
    Hinotsu, Shiro
    Takata, Minoru
    Kiura, Katsuyuki
    CLINICAL LUNG CANCER, 2017, 18 (01) : 92 - 95
  • [7] Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)
    Pitiyarachchi, Omali
    Tan, Aaron C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
  • [8] Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better
    Hoe, Hui Jing
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (31) : 4849 - +
  • [9] Ado-trastuzumab for the treatment of metastatic HER2-amplified breast cancer patients previously treated with pertuzumab
    Al Rabadi, L. S.
    Kaempf, A.
    Lim, J. Y.
    Saraceni, M. M.
    Savin, M. A.
    Mitri, Z. I.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
    Smit, Egbert F.
    FUTURE ONCOLOGY, 2024, 20 (27) : 1961 - 1971
12345